Legal Fix – Portugal
Legal Fix – Portugal – Portugal’s maverick drug laws a credible global model? To see more go to www.youtube.com Follow us on Facebook (goo.gl or Twitter (www.twitter.com After suffering the highest instance of drug-related deaths in all Europe, Portugal took a brave decision and decriminalised all drugs. Ten years on, is it a success story for other nations to follow? On the streets of Lisbon drug users light up wherever they want. One police officer tells us the girl across the street is smoking crack. He complains, but few share his sentiment. “Considering drug users as criminals just because they are using drugs is not a very realistic approach”, a Portuguese drug addiction officer argues. He has just had an interview with a sixteen-year-old boy caught smoking hashish. No punishment was handed out, just advice. In Portugal it’s now seen as a health problem, rather than a criminal one. Brendan Hughes of the European Monitoring Centre for Drugs says it is very difficult to analyse the success of the law. He points to one very interesting fact: “In 10 years of governments in Portugal, where they have changed from left to centre-right to left, back to centre-right, drugs have stayed off the agenda”. Due to the economic crisis, funding for the rehabilitation of drug offenders is going to be very seriously hit. For Dr Goulao, the public face of the law, it comes at the worst possible time. “I believe that more people will turn to drugs and alcohol.” A Film By SBS Distributed By Journeyman Pictures …
Upcoming BioPharma Catalyst Trades to Consider
Filed under: drug treatment news 2011
An FDA Decision is expected on November 30th for its supplemental New Drug Application (SNDA) to the US FDA for Promacta (eltrombopag) as a treatment for thrombocytopenia in adults with chronic hepatitis C infection to enable the initiation of …
Read more on Reuters
US cost warning over drugs to treat "normal" ageing
Filed under: drug treatment news 2011
Among these insured individuals, the use of drugs to treat the physical impact associated with normal ageing was up 18.5% from 2006 to 2011, and costs increased nearly 46%, says the research, which has been presented at the annual meeting of the …
Read more on PharmaTimes